Loading...
Loading...
FRLN| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 22.9M |
| Operating I/L | -23.5M |
| Other Income/Expense | 8.7M |
| Interest Income | 0.3M |
| Pretax | -14.8M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -14.9M |
Freeline Therapeutics Holdings plc is a clinical-stage biotechnology company specializing in adeno-associated virus (AAV) vector-mediated gene therapies for inherited systemic debilitating diseases. Its lead product candidate, verbrinacogene setparvovec (FLT180a), is in Phase 1/2 clinical trials for hemophilia B treatment. The company also has FLT190 in Phase 1/2 trials for Fabry disease and FLT201 for type 1 Gaucher disease. With a focus on gene therapy, Freeline Therapeutics generates revenue through the development and commercialization of transformative treatments for genetic disorders, catering to a niche market with high unmet medical needs.
